In this study, Cardinal Health Real-World Evidence and Insights examined the real-world adoption of darolutamide-based doublet therapy (DT) and triplet therapy (TT) regimens across U.S. community urology practices. Through this analysis, they were able to:
- Profile the real-world clinical and demographic characteristics of metastatic hormone sensitive prostate cancer (mHSPC) patients
- Characterize treatment utilization and sequencing patterns
- Identify early adoption trends
- Provide actionable insights